We recently published a list of 15 Stocks ChatGPT Predicts Could Make You Wealthy in 10 Years. In this article, we are going ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Johnson & Johnson is like the Fort Knox of dividend stocks. The healthcare company has an AAA bond rating. That's tied for ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular ... noting that sales from ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Johnson & Johnson (NYSE:JNJ) shares declined sharply Wednesday, as the company, fresh off a $14.6-billion deal to buy neurological drugmaker Intra-Cellular (NASDAQ:ITCI), reported fourth-quarter sales ...

The New Jersey-based drugmaker expects 2025 sales of between $90.9 billion and $91.7 billion, and to earn between $10.75 and ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

When most of us think of investing in stocks, we think of the potential gains -- or unfortunately, in some cases, losses -- ...

Key Takeaways The Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best cheap stocks to ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE ... In addition, the Medtech sector also showed ...